Public disclosure of inside information according to article 17 MAR
4basebio AG: KROMI takeover offer will not be pursued further
4basebio AG has decided today to no longer pursue the takeover offer to the shareholders of KROMI Logistik AG. An offer document from 4basebio AG to the shareholders of KROMI Logistik AG will therefore not be published.
4basebio AG was informed today by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungen, BaFin) during a hearing of the offer procedure that the shares of 4basebio AG offered by it as exchange shares are not considered liquid shares within the meaning of the WpÜG. With regard to the requirements for the liquidity of the shares offered for exchange, BaFin refers to a decision of the Higher Regional Court (OLG) of Frankfurt am Main dated 11 January 2021, in which the court agrees with an opinion according to which, among other things, a free float with a market capitalisation of at least EUR 500 million must exist in the class of shares offered. 4basebio AG will not be able to meet the requirements for the liquidity of its shares stated therein, just as, in the opinion of the company, most listed companies cannot.
4basebio AG submitted the offer document to the shareholders of KROMI Logistik AG on February 11, 2021. Following the expiry of the 10-day review period, the company is now expecting a prohibition order from BaFin relating to the publication of an offer document to the shareholders of KROMI Logistik AG on the basis of the hearing and has therefore decided today not to pursue the takeover offer in order to avoid further costs.
About 4basebio AG:
4basebio AG (renamed 2invest AG by resolution of the Annual General Meeting on 28 January 2021) is a listed company that acquires, holds, manages and sells investments in corporations and partnerships, in particular - but not exclusively - in the biotechnology, life science and IT sectors in Germany and abroad.
Global investments or investments in unlisted companies or financial instruments are also possible. Investment decisions are made on the basis of attractive risk-reward profiles. The focus is on achieving a risk-adequate, long-term total return. The company is listed in the Prime Standard of the Frankfurt Stock Exchange (ticker: 2INV; ISIN: DE000A2YN801).
More information: https://4basebioag.com
For further information please contact:
Board of Directors
Dr Robert Mayer, Manager IR
Tel: +49 171 3876540
### This publication is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Certain statements contained in this press release that do not relate to proven financial results or other historical data should be considered forward-looking, meaning that such statements are primarily predictions of future results, trends, plans or objectives. These statements should not be considered as total guarantees because, by their nature, they are subject to known and unknown risks and uncertainties and may be affected by other factors that could cause 4basebio AG's actual results, plans and objectives to differ materially from any stated conclusions or implied predictions contained in such statements. 4basebio undertakes no obligation to publicly update or revise any of these statements, whether as a result of new information, future results or otherwise. ##
Ziegelhäuser Landstr. 3
|+49 171 3876540
|Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate